MAR002 in healthy men

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

MAR002 is given by subcutaneous injection to healthy male volunteers in a Phase 1 interventional trial to characterize safety and tolerability. Eligible participants who meet weight and BMI requirements will be randomized to receive MAR002 or placebo and will undergo clinical monitoring, laboratory testing, and adverse event reporting. Key exclusion criteria include prior pituitary disorders, recent acute illness or blood donation, positive HIV/hepatitis tests, substance or nicotine use, and a history of cancer. The single-site study is sponsored by Marea Therapeutics and conducted in Tempe, Arizona.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Willingness to provide written informed consent
2. Age 18 to 40
3. Weight 55 to 95 kg
4. Body mass index (BMI) 18 to 30 kg/m2
5. Healthy men

Exclusion Criteria:

1. History of hypersensitivity to monoclonal antibodies or study drug
2. Participation in any other investigational drug study
3. History of cancer
4. Recent acute illness
5. Positive test for HIV, hepatitis B/C
6. History of substance abuse or nicotine use
7. Recent blood donation
8. History of pituitary disorder
9. Any condition that prevents the participant from complying with study procedures

Where it's running

• Marea Site
  Tempe, Arizona, United States Recruiting

Study contacts

• Study coordinator: Andrew Lane
• Email: mar-201-info@mareatx.com
• Phone: 415-766-3610

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NTQ6179 tablets first-in-human test in healthy adults

  This phase 1 study tests a single oral dose of NTQ6179 vs placebo in healthy adults to see if it is safe and how the body processes the drug.

  Recruiting Phase 1 Nanjing Chia-tai Tianqing Pharmaceutical · Beijing · NCT07909837

• Test MAR002 for acromegaly in adults on or off medical therapy

  This study tests whether subcutaneous MAR002 is safe and tolerable in adults with acromegaly, compared with a placebo, over 10 weeks.

  Recruiting at 3 sites Phase 2 Marea Therapeutics · Phoenix, Arizona and 2 other locations · NCT07641179

• Octreotide SC Depot in Acromegaly: Real-World Safety and Effectiveness

  This study follows people with acromegaly who are using octreotide subcutaneous depot to see how it works and how safe it is over up to two years in everyday clinical practice.

  Recruiting at 4 sites Camurus AB · Aachen and 6 other locations · NCT07583563

• Pasireotide LAR and bone health in adults with acromegaly

  This study will test whether switching adults with uncontrolled acromegaly to pasireotide LAR changes bone turnover and the risk of vertebral fractures.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, RM · NCT07179926

• Assessing Debio 4126 for treating acromegaly in patients on somatostatin analogs

  This study is testing if a new treatment called Debio 4126 can help people with acromegaly who are already on somatostatin analogs keep their IGF-1 levels in check better than a placebo.

  Recruiting at 72 sites Phase 3 Debiopharm International SA · Los Angeles, California and 73 other locations · NCT06930625

• Evaluating the effects of acromegaly on hand and foot dimensions and movement

  This study looks at how acromegaly affects the size and movement of hands and feet in patients to better understand the physical changes caused by the condition.

  Recruiting Istituto Auxologico Italiano · Milan · NCT05964712

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.